Type 2 Diabetes Mellitus, Healthy Subjects
Conditions
Brief summary
Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal administration Secondary Objectives: * To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide (M19) after a single oral dose of sotagliflozin and an IV microdose of a 14C-sotagliflozin tracer without charcoal administration * To assess the safety and tolerability of single doses of sotagliflozin when administered with and without charcoal
Detailed description
Study duration per participant is up to 54 days including a screening period of up to 28 days, period 1 of 8 days, period 2 of 8 days, a washout period of at least 10 days, and a follow up period of 12-16 days. The oral drug Sotagliflozin is metabolized by the liver and released in the bile juice into the intestine. Ingestion of charcoal a few hours after the drug administration circumvents the re-uptake of the drug from the intestine back into the blood circulation; instead, Sotagliflozin is eliminated with the feces. By comparison of Sotagliflozin drug administration with and without charcoal, the extent of this so-called enterohepatic circulation can be assessed.
Interventions
Pharmaceutical form: Tablet Route of administration: Oral
DRUG14C-microtracer
Pharmaceutical form: Solution for injection Route of administration: Intravenous
DRUGCharcoal
Pharmaceutical form: Granules for suspension Route of administration: Oral
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
: * Male or female subjects, between 18 and 55 years of age, inclusive. * Body weight between 50.0 and 120.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive. BMI between 30.0 and 32.0 is acceptable if investigator judges the subject to have a high muscle mass. * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * Normal vital signs, ECG and laboratory parameters.
Exclusion criteria
* Any history or presence of clinically relevant abnormalities at screening which could interfere with the objectives of the study or the safety of the subject's participation. * Blood donation (400 mL) within 3 months before inclusion. * History or presence of drug or alcohol abuse. * Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study. Excessive consumption of beverages containing xanthine bases. * If female, pregnancy (defined as positive β-Human Chorionic Gonadotropin blood test), breast-feeding. * Any medication (including St John's Wort) within 14 days before inclusion with the exception of menopausal hormone replacement therapy; any vaccination within last 28 days; any biologics given within last 4 months. * Any subject in the exclusion period of a previous study. * Any subject who cannot be contacted in case of emergency. * Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies. * Positive result on urine drug screen. * Positive alcohol test. * Participation in a study in which radioisotopes were administered or in which subject was exposed to any radiation other than normal background radiation within the 12 months before the screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) parameter: Absolute Bioavailability (F) | Baseline to Day 8 of period 1 (without charcoal) | Absolute Bioavailability (F) will be a composite endpoint and include Area under plasma concentration (AUC) dose normalized for intravenous (IV) 14C-IMP AUClast dose normalized for oral Investigational Medicinal Product (IMP) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of PK parameter: AUC for IMP metabolite | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve extrapolated to infinity for IMP metabolite |
| Assessment of PK parameter: AUC for IV 14C-IMP | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve extrapolated to infinity for IV 14C-IMP |
| Assessment of PK parameter: AUC for 14C-IMP metabolite | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve extrapolated to infinity for 14C-IMP metabolite |
| Assessment of PK parameter: Area under curve versus time (AUClast) for oral IMP | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for oral IMP |
| Assessment of PK parameter: AUClast for IMP metabolite | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IMP metabolite |
| Assessment of PK parameter: AUClast for IV 14C-IMP | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IV 14C-IMP |
| Assessment of PK parameter: AUClast for 14C-IMP metabolite | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve |
| Assessment of PK parameter: Cmax for oral IMP | Baseline to Day 8 of each period | Maximum plasma concentration observed for oral IMP |
| Assessment of PK parameter: Cmax for IMP metabolite | Baseline to Day 8 of each period | Maximum plasma concentration observed for IMP metabolite |
| Assessment of PK parameter: Cmax for IV 14C-IMP | Baseline to Day 8 of each period | Maximum plasma concentration observed for IV 14C-IMP |
| Assessment of PK parameter: Cmax for 14C-IMP metabolite | Baseline to Day 8 of each period | Maximum plasma concentration observed for 14C-IMP metabolite |
| Assessment of PK parameter: tmax for oral IMP | Baseline to Day 8 of each period | Time to reach Cmax for oral IMP |
| Assessment of PK parameter: Area under the curve (AUC) for oral investigational medicinal product (IMP) | Baseline to Day 8 of each period | Area under the plasma concentration versus time curve extrapolated to infinity for oral IMP |
| Assessment of PK parameter: tmax for IV 14C-IMP | Baseline to Day 8 of each period | Time to reach Cmax for IV 14C-IMP |
| Assessment of PK parameter: tmax for 14C-IMP metabolite | Baseline to Day 8 of each period | Time to reach Cmax for 14C-IMP metabolite |
| Assessment of PK parameter: t1/2z for oral IMP | Baseline to Day 8 of each period | Terminal half-life (t1/2z) associated with the terminal slope for oral IMP |
| Assessment of PK parameter: t1/2z for IV 14C-IMP | Baseline to Day 8 of each period | Terminal half-life (t1/2z) associated with the terminal slope for IV 14C-IMP |
| Assessment of PK parameter: Clearance (CL/F) for oral IMP | Baseline to Day 8 of each period | Apparent total body clearance for oral IMP |
| Assessment of PK parameter: Clearance (CL/F) for IV 14C-IMP | Baseline to Day 8 of each period | Apparent total body clearance for IV 14C-IMP |
| Assessment of PK parameter: Vz/F for oral IMP | Baseline to Day 8 of each period | Apparent volume of distribution for oral IMP |
| Assessment of PK parameter: Vz/F for IV 14C-IMP | Baseline to Day 8 of each period | Apparent volume of distribution for IV 14C-IMP |
| Assessment of PK parameter: Vdss/F for oral IMP | Baseline to Day 8 of each period | Apparent volume of distribution at the steady state for oral IMP |
| Assessment of PK parameter: Vdss/F for IV 14C-IMP | Baseline to Day 8 of each period | Apparent volume of distribution at the steady state for IV 14C-IMP |
| Safety: Adverse events | Baseline to Day 8 of each period | Number of subjects with adverse events including serious, non-serious, and treatment emergent adverse events |
| Assessment of PK parameter: tmax for IMP metabolite | Baseline to Day 8 of each period | Time to reach Cmax for IMP metabolite |
Countries
United Kingdom
Outcome results
None listed